Publication Name	World Journal of Gastroenterology
Manuscript ID	80143
Country	China

Received	2022-09-18 11:41
Peer-Review Started	2022-09-18 11:43
To Make the First Decision
Return for Revision	2022-10-30 18:20
Revised	2022-11-07 12:21
Second Decision	2022-11-22 03:28
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-11-23 02:44
Articles in Press	2022-11-23 02:44
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-11-28 02:17
Publish the Manuscript Online	2022-12-19 10:48

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Alterations of the gut microbiota in coronavirus disease 2019 and its therapeutic potential
Manuscript Source	Invited Manuscript
All Author List	Hui Xiang and Qi-Ping Liu
Funding Agency and Grant Number
Corresponding Author	Hui Xiang, MM, Doctor, Doctor, Department of Infectious Disease, Chongqing University Three Gorges Hospital, No. 165 Xincheng Road, Chongqing 404100, China. xianghui9312@163.com
Key Words	COVID-19; SARS-CoV-2; Angiotensin-converting enzyme 2; Gut microbiota; Dysbiosis; Lung
Core Tip	Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global health threat. SARS-CoV-2 infects host cells through binding to angiotensin-converting enzyme 2. COVID-19 patients exhibit gut dysbiosis. Here, the gut microbiota alterations in COVID-19 are summarized. The pathways and possible mechanisms of dysbiosis caused by SARS-CoV-2, as well as the impact of the gut microbiota and its metabolites on the inflammatory response and antiviral effects during the course of the disease are also described. Therefore, targeting the gut microbiota should be considered a promising strategy for COVID-19 prevention, treatment, and prognostic assessment.
Publish Date	2022-12-19 10:48
Citation	Xiang H, Liu QP. Alterations of the gut microbiota in coronavirus disease 2019 and its therapeutic potential. World J Gastroenterol 2022; 28(47): 6689-6701
URL	https://www.wjgnet.com/1007-9327/full/v28/i47/6689.htm
DOI	https://dx.doi.org/10.3748/wjg.v28.i47.6689

Full Article (PDF)	WJG-28-6689.pdf
Full Article (Word)	WJG-28-6689.docx
Manuscript File	80143_Auto_Edited-LM.docx
Answering Reviewers	80143-Answering reviewers.pdf
Audio Core Tip	80143-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	80143-Conflict-of-interest statement.pdf
Copyright License Agreement	80143-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	80143-Language certificate.pdf
Peer-review Report	80143-Peer-review(s).pdf
Scientific Misconduct Check	80143-Bing-Chen YL-2.png
Scientific Editor Work List	80143-Scientific editor work list.pdf
CrossCheck Report	80143-CrossCheck report.pdf